Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAN-NEURO-02
- Development stage
- Preclinical
- Lead developer
- Kantify
- Modality
- Small Molecules
01
Overview
KAN-NEURO-02 is a first-in-class small molecule discovered via the Sapian™ AI platform, designed to modulate a sodium channel for the treatment of neuromuscular disorders. Developed by Kantify in collaboration with INSERM (specifically the Institut des Neurosciences de Montpellier - ITN and the Institut de Génomique Fonctionnelle - IGF), the program is currently in the preclinical stage. The specific sodium channel subtype and the nature of the modulation (e.g., inhibition or activation) have not been publicly disclosed, but the approach represents a novel mechanism for addressing neuromuscular pathology.
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on KAN-NEURO-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAN-NEURO-02.